Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: An example of long-acting dual hormonal therapeutics

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9328-9341

  Sun, Chengzao ^a   Trevaskis, James L ^a   Jodka, Carolyn M ^a   Neravetla, Swetha ^a   Griffin, Pete ^a   Xu, Kui ^a   Wang, Yan ^a   Parkes, David G ^a   Forood, Bruce ^a   Ghosh, Soumitra S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

40 METHOXY POLY(ETHYLENE GLYCOL)MALEIMIDE DESLYSINE 1 DAVALINTIDE; AC 3082; AC 3174; AMYLIN; AMYLIN RECEPTOR; CALCITONIN RECEPTOR; DAVALINTIDE; EXENATIDE AMYLINOMIMETIC PEPTIDE HYBRID; EXENATIDE[1-28]; EXENATIDE[1-28] GLYCYLGLYCYL GLYCINE DAVALINTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCINE; HORMONE RECEPTOR STIMULATING AGENT; HYBRID PROTEIN; L14 EXENATIDE; L14 EXENATIDE 40 METHOXY POLY(ETHYLENE GLYCOL)MALEIMIDE; L14 EXENATIDE GLYCYLGLYCYL GLYCINE DAVALINTIDE; MACROGOL DERIVATIVE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FEMALE; FOOD INTAKE; HORMONAL THERAPY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PROTEIN MODIFICATION; RAT; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; DRUG DESIGN; FEMALE; HUMANS; ISLET AMYLOID POLYPEPTIDE; MALE; METABOLIC DISEASES; MICE; MODELS, MOLECULAR; OBESITY; PEPTIDE HORMONES; PEPTIDES; PEPTIDOMIMETICS; POLYETHYLENE GLYCOLS; PROTEIN STRUCTURE, SECONDARY; RATS; TIME FACTORS; VENOMS;

EID: 84889244329     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401418s     Document Type: Article

References (68)

1. Mack, C. M.; Soares, C. J.; Wilson, J. K.; Athanacio, J. R.; Turek, V. F.; Trevaskis, J. L.; Roth, J. D.; Smith, P. A.; Gedulin, B.; Jodka, C. M.; Roland, B. L.; Adams, S. H.; Lwin, A.; Herich, J.; Laugero, K. D.; Vu, C.; Pittner, R.; Paterniti, J. R., Jr.; Hanley, M.; Ghosh, S.; Parkes, D. G. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight Int. J. Obes. 2010, 34, 385-395
2. Pan, C. Q.; Buxton, J. M.; Yung, S. L.; Tom, I.; Yang, L.; Chen, H.; MacDougall, M.; Bell, A.; Claus, T. H.; Clairmont, K. B.; Whelan, J. P. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist J. Biol. Chem. 2006, 281, 12506-12515 (Pubitemid 43855337)
3. Day, J. W.; Ottaway, N.; Patterson, J. T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D. J.; Chaudhary, N.; Holland, J.; Hembree, J.; Abplanalp, W.; Grant, E.; Ruehl, J.; Wilson, H.; Kirchner, H.; Lockie, S. H.; Hofmann, S.; Woods, S. C.; Nogueiras, R.; Pfluger, P. T.; Perez-Tilve, D.; DiMarchi, R.; Tschop, M. H. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. 2009, 5, 749-757
4. Pocai, A.; Carrington, P. E.; Adams, J. R.; Wright, M.; Eiermann, G.; Zhu, L.; Du, X.; Petrov, A.; Lassman, M. E.; Jiang, G.; Liu, F.; Miller, C.; Tota, L. M.; Zhou, G.; Zhang, X.; Sountis, M. M.; Santoprete, A.; Capito, E.; Chicchi, G. G.; Thornberry, N.; Bianchi, E.; Pessi, A.; Marsh, D. J.; SinhaRoy, R. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 2009, 58, 2258-2266
5. Bhat, V. K.; Kerr, B. D.; Flatt, P. R.; Gault, V. A. A novel GIP-Oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties Biochem. Pharmacol. 2013, 85, 1655-1662
6. Bhat, V. K.; Kerr, B. D.; Vasu, S.; Flatt, P. R.; Gault, V. A. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice Diabetologia 2013, 56, 1417-1424
7. Mack, C. M.; Smith, P. A.; Athanacio, J. R.; Xu, K.; Wilson, J. K.; Reynolds, J. M.; Jodka, C. M.; Lu, M. G.; Parkes, D. G. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide Diabetes Obes. Metab. 2011, 13, 1105-1113
8. Papo, N.; Silverman, A. P.; Lahti, J. L.; Cochran, J. R. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 14067-14072
9. Foote, J. Immunology. Isomeric antibodies Science 2003, 299, 1327-1328
10. James, L. C.; Roversi, P.; Tawfik, D. S. Antibody multispecificity mediated by conformational diversity Science 2003, 299, 1362-1367 (Pubitemid 36254643)
11. Baker, M. Upping the ante on antibodies Nat. Biotechnol. 2005, 23, 1065-1072 (Pubitemid 41486384)
12. Wu, C.; Ying, H.; Grinnell, C.; Bryant, S.; Miller, R.; Clabbers, A.; Bose, S.; McCarthy, D.; Zhu, R. R.; Santora, L.; Davis-Taber, R.; Kunes, Y.; Fung, E.; Schwartz, A.; Sakorafas, P.; Gu, J.; Tarcsa, E.; Murtaza, A.; Ghayur, T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin Nat. Biotechnol. 2007, 25, 1290-1297 (Pubitemid 350076510)
13. Chames, P.; Baty, D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009, 1, 539-547
14. Fitzgerald, J.; Lugovskoy, A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways MAbs 2011, 3, 299-309
15. Lafleur, D. W.; Abramyan, D.; Kanakaraj, P.; Smith, R. G.; Shah, R. R.; Wang, G.; Yao, X. T.; Kankanala, S.; Boyd, E.; Zaritskaya, L.; Nam, V.; Puffer, B. A.; Buasen, P.; Kaithamana, S.; Burnette, A. F.; Krishnamurthy, R.; Patel, D.; Roschke, V. V.; Kiener, P. A.; Hilbert, D. M.; Barbas, C. F. Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides MAbs 2013, 5, 208-218
16. Davidson, M. B.; Bate, G.; Kirkpatrick, P. Exenatide Nat. Rev. Drug Discovery 2005, 4, 713-714
17. Drucker, D. J.; Dritselis, A.; Kirkpatrick, P. Liraglutide Nat. Rev. Drug Discovery 2010, 9, 267-268
18. Pullman, J.; Darsow, T.; Frias, J. P. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes Vasc. Health Risk Manag. 2006, 2, 203-212 (Pubitemid 44275457)
19. Lebovitz, H. E. Adjunct therapy for type 1 diabetes mellitus Nat. Rev. Endocrinol. 2010, 6, 326-334
20. Tschop, M. H.; DiMarchi, R. D. Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies Diabetes 2012, 61, 1309-1314
21. Roth, J. D.; Trevaskis, J. L.; Turek, V. F.; Parkes, D. G. "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations Brain Res. 2010, 1350, 86-94
22. Cegla, J.; Tan, T. M.; Bloom, S. R. Gut-brain cross-talk in appetite regulation Curr. Opin. Clin. Nutr. Metab. Care 2010, 13, 588-593
23. Neary, N. M.; Small, C. J.; Druce, M. R.; Park, A. J.; Ellis, S. M.; Semjonous, N. M.; Dakin, C. L.; Filipsson, K.; Wang, F.; Kent, A. S.; Frost, G. S.; Ghatei, M. A.; Bloom, S. R. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively Endocrinology 2005, 146, 5120-5127 (Pubitemid 41653025)
24. Talsania, T.; Anini, Y.; Siu, S.; Drucker, D. J.; Brubaker, P. L. Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice Endocrinology 2005, 146, 3748-3756 (Pubitemid 41175742)
25. Reidelberger, R. D.; Haver, A. C.; Apenteng, B. A.; Anders, K. L.; Steenson, S. M. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats Obesity 2011, 19, 121-127
26. Bello, N. T.; Kemm, M. H.; Ofeldt, E. M.; Moran, T. H. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299, R945-R952
27. Lutz, T. A. The interaction of amylin with other hormones in the control of eating Diabetes Obes. Metab. 2013, 15, 99-111
28. Zuger, D.; Forster, K.; Lutz, T. A.; Riediger, T. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli Physiol. Behav. 2013, 112-113C, 61-69
29. Trevaskis, J. L.; Turek, V. F.; Griffin, P. S.; Wittmer, C.; Parkes, D. G.; Roth, J. D. Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin? Physiol. Behav. 2010, 100, 187-195
30. Irwin, N.; Hunter, K.; Montgomery, I. A.; Flatt, P. R. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice Diabetes Obes. Metab. 2013, 15, 650-659
31. Roth, J. D.; Roland, B. L.; Cole, R. L.; Trevaskis, J. L.; Weyer, C.; Koda, J. E.; Anderson, C. M.; Parkes, D. G.; Baron, A. D. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 7257-7262 (Pubitemid 351754465)
32. Trevaskis, J. L.; Coffey, T.; Cole, R.; Lei, C.; Wittmer, C.; Walsh, B.; Weyer, C.; Koda, J.; Baron, A. D.; Parkes, D. G.; Roth, J. D. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms Endocrinology 2008, 149, 5679-5687
33. Chan, J. L.; Roth, J. D.; Weyer, C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development J. Invest. Med. 2009, 57, 777-783
34. Trevaskis, J. L.; Lei, C.; Koda, J. E.; Weyer, C.; Parkes, D. G.; Roth, J. D. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats Obesity 2010, 18, 21-26
35. Young, A. A. (2005) Amylin: Physiology and Pharmacology; Elsevier Academic Press, San Diego, CA.
36. Riediger, T.; Lutz, T. A.; Schmid, H. A.; Scharrer, E. The Area Postrema as a Major Target for Peptides Controlling Food Intake; Abstracts; New Orleans: Society for Neuroscience: Washington, DC; 2000, pp 369.310.
37. Hargrove, D. M.; Kendall, E. S.; Reynolds, J. M.; Lwin, A. N.; Herich, J. P.; Smith, P. A.; Gedulin, B. R.; Flanagan, S. D.; Jodka, C. M.; Hoyt, J. A.; McCowen, K. M.; Parkes, D. G.; Anderson, C. M. Biological activity of AC3174, a peptide analog of exendin-4 Regul. Pept. 2007, 141, 113-119 (Pubitemid 46482688)
38. Liu, Q.; Adams, L.; Broyde, A.; Fernandez, R.; Baron, A. D.; Parkes, D. G. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats Cardiovasc. Diabetol. 2010, 9, 32
39. Liu, Q.; Anderson, C.; Broyde, A.; Polizzi, C.; Fernandez, R.; Baron, A.; Parkes, D. G. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Cardiovasc. Diabetol. 2010, 9, 76
40. Lopez de Maturana, R.; Willshaw, A.; Kuntzsch, A.; Rudolph, R.; Donnelly, D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1 J. Biol. Chem. 2003, 278, 10195-10200 (Pubitemid 36800279)
41. Westermark, P.; Engstrom, U.; Johnson, K. H.; Westermark, G. T.; Betsholtz, C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 5036-5040
42. Roberts, A. N.; Leighton, B.; Todd, J. A.; Cockburn, D.; Schofield, P. N.; Sutton, R.; Holt, S.; Boyd, Y.; Day, A. J.; Foot, E. A. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9662-9666 (Pubitemid 20030693)
43. Roth, J. D.; Mack, C. M.; Soares, C. J.; Ghosh, S. S.; Parkes, D. G. Amylin-based pharmacotherapy-past, present & future Immunol., Endocr. Metab. Agents Med. Chem. 2008, 8, 317-324
44. Caliceti, P.; Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug. Delivery Rev. 2003, 55, 1261-1277 (Pubitemid 37464561)
45. Fee, C. J. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules Biotechnol. Bioeng. 2007, 98, 725-731 (Pubitemid 350032676)
46. Fee, C. J.; Van Alstine, J. M. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjugate Chem. 2004, 15, 1304-1313 (Pubitemid 39552020)
47. Nakaoka, R.; Tabata, Y.; Yamaoka, T.; Ikada, Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification J. Controlled Release 1997, 46, 253-261 (Pubitemid 27132849)
48. Kochendoerfer, G. Chemical and biological properties of polymer-modified proteins Expert Opin. Biol. Ther. 2003, 3, 1253-1261 (Pubitemid 38004696)
49. Ryan, S. M.; Mantovani, G.; Wang, X.; Haddleton, D. M.; Brayden, D. J. Advances in PEGylation of important biotech molecules: delivery aspects Expert Opin. Drug Delivery 2008, 5, 371-383 (Pubitemid 351721718)
50. Fishburn, C. S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 2008, 97, 4167-4183
51. Bailon, P.; Won, C. Y. PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 2009, 6, 1-16
52. Kang, J. S.; Deluca, P. P.; Lee, K. C. Emerging PEGylated drugs Expert Opin. Emerg. Drugs 2009, 14, 363-380
53. Jevsevar, S.; Kunstelj, M.; Porekar, V. G. PEGylation of therapeutic proteins Biotechnol J 2010, 5, 113-128
54. Milla, P.; Dosio, F.; Cattel, L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery Curr. Drug Metab. 2012, 13, 105-119
55. Pasut, G.; Veronese, F. M. State of the art in PEGylation: the great versatility achieved after forty years of research J. Controlled Release 2012, 161, 461-472
56. Grace, M. J.; Lee, S.; Bradshaw, S.; Chapman, J.; Spond, J.; Cox, S.; Delorenzo, M.; Brassard, D.; Wylie, D.; Cannon-Carlson, S.; Cullen, C.; Indelicato, S.; Voloch, M.; Bordens, R. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway J. Biol. Chem. 2005, 280, 6327-6336 (Pubitemid 40341179)
57. Dhalluin, C.; Ross, A.; Leuthold, L. A.; Foser, S.; Gsell, B.; Muller, F.; Senn, H. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers Bioconjugate Chem. 2005, 16, 504-517 (Pubitemid 40696041)
58. Gaertner, H. F.; Offord, R. E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins Bioconjugate Chem. 1996, 7, 38-44
59. Kinstler, O.; Molineux, G.; Treuheit, M.; Ladd, D.; Gegg, C. Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 2002, 54, 477-485 (Pubitemid 34615544)
60. Shaunak, S.; Godwin, A.; Choi, J. W.; Balan, S.; Pedone, E.; Vijayarangam, D.; Heidelberger, S.; Teo, I.; Zloh, M.; Brocchini, S. Site-specific PEGylation of native disulfide bonds in therapeutic proteins Nat. Chem. Biol. 2006, 2, 312-313 (Pubitemid 43787211)
61. Brocchini, S.; Godwin, A.; Balan, S.; Choi, J. W.; Zloh, M.; Shaunak, S. Disulfide bridge based PEGylation of proteins Adv. Drug Delivery Rev. 2008, 60, 3-12 (Pubitemid 350181163)
62. Fontana, A.; Spolaore, B.; Mero, A.; Veronese, F. M. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase Adv. Drug Delivery Rev. 2008, 60, 13-28 (Pubitemid 350181164)
63. Zhang, C.; Yang, X. L.; Yuan, Y. H.; Pu, J.; Liao, F. Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives BioDrugs 2012, 26, 209-215
64. Wang, Y.; Qu, Y.; Bellows, C. L.; Ahn, J. S.; Burkey, J. L.; Taylor, S. W. Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS Bioanalysis 2012, 4, 2141-2152
65. Caldwell, G. W.; Masucci, J. A.; Yan, Z.; Hageman, W. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet. 2004, 29, 133-143 (Pubitemid 38828626)
66. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283, 46-58 (Pubitemid 27438945)
67. Bendele, A.; Seely, J.; Richey, C.; Sennello, G.; Shopp, G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol. Sci. 1998, 42, 152-157 (Pubitemid 28211143)
68. Conover, C.; Lejeune, L.; Linberg, R.; Shum, K.; Shorr, R. G. Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat Artif. Cells, Blood Substitutes Immobil. Biotechnol. 1996, 24, 599-611 (Pubitemid 26396013)